Experimental drug helps patients lose nearly a quarter of body weight in early trials

Experimental drug helps patients lose nearly a quarter of body weight in early trials

Novo Nordisk's amycretin targets two hunger hormones in a single molecule, advancing to phase 3 trials

An experimental weight-loss medication was shown to help people lose nearly 25% of their body weight in early-stage 1a/2b trials. (iStock)

Novo Nordisk presented the latest findings at the American Diabetes Association in Chicago on June 22. ((Photo by LISELOTTE SABROE/Scanpix Denmark/AFP via Getty Images))

"Obesity is a chronic, multifactorial disease that requires a comprehensive, long-term approach," a doctor said. (iStock)